ReviewMedical oncology (Northwood, London, England)2025
Characteristic of Aldosterone-Producing adrenocortical carcinoma: review of the literature.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary aldosteronism.Nature reviews. Disease primers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenocortical carcinoma (ACC) is a rare tumor, and aldosterone-producing-ACCs are even less frequent. Data on aldosterone-producing ACC (APAC) are scarce and most of the current knowledge derives from case reports. Therefore, aiming to summarize the main clinical features described in this aggressive cancer, we conducted a review of the PubMed database on this topic from 2005 to 2024. We included only studies with histological confirmation of ACC and biochemical evidence of aldosterone hypersecretion, identifying 27 reported cases of APAC. Epidemiological and radiological features of APACs resemble those of ACCs in general, whereas the median Ki67 index appears higher (25% vs. 10-14%) and the prevalence of ENSAT stage I greater (18% vs. 5-6%) compared with the overall ACC population, although a meaningful comparison would require a specifically designed prospective study. This is the first review assessing Ki67 and ENSAT stage in APACs based on previously published cases. To date, no significant differences have been described in morphological, clinical, or molecular aspects between these two types of ACC. Larger and higher-quality studies are needed to confirm these findings.
Indexed as
Identifiers
41385120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.